Ambeed.cn

首页 / / / CDK / Abemaciclib methanesulfonate

Abemaciclib methanesulfonate {[allProObj[0].p_purity_real_show]}

货号:A144902

Abemaciclib methanesulfonate 是一种选择性的 CDK4/6 抑制剂,对 CDK4/6 具有高亲和力,抑制 CDK4/CDK6IC50 分别为 2 nM 和 10 nM。Abemaciclib methanesulfonate 具有抗肿瘤作用,主要用于乳腺癌和其他 CDK4/6 依赖型癌症的研究和治疗。

Abemaciclib methanesulfonate 化学结构 CAS号:1231930-82-7
Abemaciclib methanesulfonate 化学结构
CAS号:1231930-82-7
Abemaciclib methanesulfonate 3D分子结构
CAS号:1231930-82-7
Abemaciclib methanesulfonate 化学结构 CAS号:1231930-82-7
Abemaciclib methanesulfonate 3D分子结构 CAS号:1231930-82-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Abemaciclib methanesulfonate 纯度/质量文件 产品仅供科研

货号:A144902 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]
Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]
Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]
更多 >
产品名称 Cdc CDK1 CDK19 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CLK 其他靶点 纯度
XL413 hydrochloride ++++

Cdc7, IC50: 3.4 nM

99%+
SU9516 +++

CDK1, IC50: 40 nM

+++

CDK2, IC50: 22 nM

++

CDK4, IC50: 200 nM

99%+
RO-3306 +++

CDK1, Ki: 20 nM

ERK,SGK 98%
R547 ++++

CDK1/CyclinB, Ki: 2 nM

++++

CDK2/CyclinE, Ki: 3 nM

++++

CDK4/CyclinD1, Ki: 1 nM

99%+
BMS-265246 ++++

CDK1/CyclinB, IC50: 6 nM

++++

CDK2/CyclinE, IC50: 9 nM

+

CDK4/CyclinD, IC50: 230 nM

99%+
NU6027 +

CDK1, Ki: 2.5 μM

+

CDK2, Ki: 1.3 μM

DNA-PK 98%
Purvalanol A ++++

Cdc2/CyclinB, IC50: 4 nM

+++

CDK2/CyclinA, IC50: 70 nM

CDK2/CyclinE, IC50: 35 nM

+

CDK4/CyclinD1, IC50: 850 nM

99%+
SCH900776 ++

CDK2, IC50: 0.16 μM

99%+
AUZ 454 ++++

CDK2(C118L), Kd: 18.6 nM

CDK2(A144C), Kd: 9.7 nM

99%+
A-674563 HCl ++

CDK2, Ki: 46 nM

PKA 99%
JNJ-7706621 ++++

CDK1/CyclinB, IC50: 9 nM

++++

CDK2/CyclinA, IC50: 4 nM

CDK2/CyclinE, IC50: 3 nM

++

CDK3/CyclinE, IC50: 58 nM

+

CDK4/CyclinD1, IC50: 253 nM

++

CDK6/CyclinD1, IC50: 175 nM

99%+
AT7519 ++

CDK1/CyclinB, IC50: 210 nM

++

CDK2/CyclinA, IC50: 47 nM

+

CDK3/CyclinE, IC50: 360 nM

++

CDK4/CyclinD1, IC50: 100 nM

+++

CDK5/p35, IC50: 13 nM

++

CDK6/CyclinD3, IC50: 170 nM

++++

CDK9/CyclinT, IC50: <10 nM

98+%
PHA-793887 ++

CDK1/CyclinB, IC50: 60 nM

++++

CDK2/CyclinA, IC50: 8 nM

CDK2/CyclinE, IC50: 8 nM

++

CDK4/CyclinD1, IC50: 62 nM

++++

CDK5/p25, IC50: 5 nM

++++

CDK7/CyclinH, IC50: 10 nM

++

CDK9/CyclinT1, IC50: 138 nM

99%+
Milciclib +

CDK1/CyclinB, IC50: 398 nM

++

CDK2/CyclinA, IC50: 45 nM

CDK2/CyclinE, IC50: 363 nM

++

CDK4/CyclinD1, IC50: 160 nM

+

CDK5/p35, IC50: 265 nM

++

CDK7/CyclinH, IC50: 150 nM

99%+
Kenpaullone +

CDK1/CyclinB, IC50: 0.4μM

+

CDK2/CyclinA, IC50: 0.68μM

CDK2/CyclinE, IC50: 7.5μM

+

CDK5/p35, IC50: 0.85μM

98%
SNS-032 +++

CDK2/CyclinA, IC50: 38 nM

CDK2/CyclinE, IC50: 48 nM

+

CDK5/p35, IC50: 340 nM

++

CDK7/CyclinH, IC50: 62 nM

++++

CDK9/CyclinT, IC50: 4 nM

99%+
Dinaciclib ++++

CDK1, IC50: 3 nM

++++

CDK2, IC50: 1 nM

++++

CDK5, IC50: 1 nM

++++

CDK9, IC50: 4 nM

99%+
PHA-767491 hydrochloride ++++

Cdc7, IC50: 10 nM

+

CDK1, IC50: 250 nM

+

CDK2, IC50: 240 nM

+

CDK5, IC50: 460 nM

+++

CDK9, IC50: 34 nM

MK2 99%
(R)-Roscovitine +

Cdc2/CyclinB, IC50: 0.65 μM

+

CDK2/CyclinA, IC50: 0.7 μM

CDK2/CyclinE, IC50: 0.7 μM

++

CDK5/p35, IC50: 0.16 μM

99%+
Narazaciclib ++++

CDK4/CyclinD1, IC50: 3.87 nM

++++

CDK6/CyclinD1, IC50: 9.82 nM

RET 99%+
Palbociclib ++++

CDK4/CyclinD1, IC50: 11 nM

CDK4/CyclinD3, IC50: 9 nM

+++

CDK6/CyclinD2, IC50: 15 nM

99%
Abemaciclib ++++

CDK4, IC50: 2 nM

++++

CDK6, IC50: 10 nM

99%
Ribociclib ++++

CDK4, IC50: 10 nM

+++

CDK6, IC50: 39 nM

98%
Palbociclib isethionate ++++

CDK4/CyclinD1, IC50: 11 nM

CDK4/CyclinD3, IC50: 9 nM

+++

CDK6/CyclinD2, IC50: 15 nM

99%+
BS-181 HCl +++

CDK7, IC50: 21 nM

99%+
(E/Z)-THZ1 dihydrochloride ++++

CDK7, IC50: 3.2 nM

99%+
LDC4297 ++++

CDK7, IC50: 0.13 nM

99%+
Senexin A +

CDK19, Kd: 0.31 μM

+

CDK8, Kd: 0.83 μM

99%
MSC2530818 ++++

CDK8, IC50: 2.6 nM

99%+
Wogonin 99%+
Riviciclib HCl ++

CDK1/CyclinB, IC50: 79 nM

+

CDK2/CyclinA, IC50: 224 nM

CDK2/CyclinE, IC50: 2.54 μM

++

CDK4/CyclinD1, IC50: 63 nM

+

CDK6/CyclinD3, IC50: 396 nM

+

CDK7/CyclinH, IC50: 2.87 μM

+++

CDK9/CyclinT1, IC50: 20 nM

99+%
LDC000067 +

CDK2, IC50: 2.441 μM

++

CDK9, IC50: 44 nM

99%
Flavopiridol +++

CDK1, IC50: 40 nM

+++

CDK2, IC50: 40 nM

+++

CDK4, IC50: 40 nM

+++

CDK6, IC50: 40 nM

+

CDK7, IC50: 300 nM

+++

CDK9, IC50: 20 nM

99%+
LY2857785 +

CDK7, IC50: 0.246 μM

+++

CDK8, IC50: 0.016 μM

+++

CDK9, IC50: 0.011 μM

99%+
AZD-5438 +++

CDK1, IC50: 16 nM

++++

CDK2, IC50: 6 nM

+++

CDK9, IC50: 20 nM

99%+
ML167 ++

CLK4, IC50: 136 nM

Dyrk1B , IC50: 1648 nM

99%+
(E/Z)-TG003 +++

mCLK1, IC50: 200 nM

mCLK4, IC50: 15 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Abemaciclib methanesulfonate 生物活性

描述 CDK4/6, forming a complex with its partner Cyclin D1/2/3, can mediate the phosphorylation of Rb in G1 cell cycle, as well as stimulating the synthesis cyclin E and D-type cyclins controlled by extracellular mitogens[1]. LY2835219 (abemaciclib) can selectively inhibit CDK4/cyclin D1 and CDK6/cyclin D1 with IC50 values of 2 nM and 10 nM (measured by enzymatic assays), respectively. Treatment with LY2835219 for 24h showed a dose-dependent inhibition of pRb-S780, with IC50 of 120 nM, and G1 arrest with EC50 of 72 nM in Colo-205 colorectal cells. Similar effect can also be observed in MCF10A and MV4-11 AML cells. LY2835219 showed the good pharmacodynamics. Oral dose>12.5 mg/kg for 24h can decrease the level of p-Rb (a phenotypic marker for cells in G1 and CDK4/6 inhibition), topisomerase II alpha (a marker for cells in S phase) and pHH3 (a marker for cells in M phase) in mice bearing colo-205 human xenografts. Oral treatment of LY2835219 on dose of 25 - 100 mg/kg for 21 days significantly inhibited the growth of colo-205 and MV4-11 xenograft mice[2]. There are 10 ongoing clinical trials using LY2835219 as a single agent or in combination for the treatment of tumors including breast, lung cancer, lymphoma and MCL, Stage IV NSCLC with a detectable KRAS mutation and breast cancer[3].
作用机制 LY2835219 is a competitive ATP CDK4/6 inhibitor[2].

Abemaciclib methanesulfonate 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
human COLO205 cells Function assay 24 h Inhibition of CDK4/6 in human COLO205 cells assessed as inhibition of Rb phosphorylation after 24 hrs by propidium iodide staining-based laser-scanning fluorescence microplate cytometric analysis 26115571
human COLO205 cells Function assay 24 h Inhibition of CDK4/6 in human COLO205 cells assessed as maximum cell cycle arrest at G1 phase after 24 hrs by propidium iodide staining-based flow cytometric analysis 26115571
insect cells Function assay 50 mins Competitive inhibition of human CDK4/cyclin D1 expressed in insect cells assessed as phosphorylation of CTRF after 50 mins by Michaelis-Menten plot analysis in presence of ATP, Ki=0.6 nM 26115571
insect cells Function assay 50 mins Inhibition of human CDK4/cyclin D1 expressed in insect cells assessed as phosphorylation of CTRF after 50 mins by microplate scintillation counter, IC50=2 nM 26115571

Abemaciclib methanesulfonate 动物研究

Dose Mice[4] (s.c.): min = 12.5 mg/kg, max = 100 mg/kg
Administration s.c.
Pharmacokinetics
Animal Rats[5]
Dose 40 mg/kg
Administration o.p.
Cmax 789 ng/ml
T1/2 10.3 h
AUC0-48h 22000
F 0.595

Abemaciclib methanesulfonate 参考文献

[1]Roskoski R Jr, et al. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res. 2016 May;107:249-275.

[2], et al. Symposium on the use of sinusoidally modulated light for the study of visual mechanisms in normal subjects, patients and animals (dogs). Electroencephalogr Clin Neurophysiol. 1967 Dec;23(6):586-7.

[3]Aleem E, Arceci RJ, et al. Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol. 2015 Apr 9;3:16.

[4]Gelbert LM, Cai S, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37.

[5]208716Orig1s000MultidisciplineR

Abemaciclib methanesulfonate 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.66mL

0.33mL

0.17mL

8.30mL

1.66mL

0.83mL

16.59mL

3.32mL

1.66mL

Abemaciclib methanesulfonate 技术信息

CAS号1231930-82-7
分子式C28H36F2N8O3S
分子量 602.699
别名
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Inert atmosphere,2-8°C

溶解度

DMSO: 9 mg/mL(14.93 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 120 mg/mL(199.1 mM),配合低频超声助溶

动物实验配方

PO 0.5% CMC-Na 40 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。